238 related articles for article (PubMed ID: 27235581)
21. Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints.
Sudan A; Livermore J; Howard SJ; Al-Nakeeb Z; Sharp A; Goodwin J; Gregson L; Warn PA; Felton TW; Perfect JR; Harrison TS; Hope WW
Antimicrob Agents Chemother; 2013 Jun; 57(6):2793-800. PubMed ID: 23571544
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of SCH39304 in murine cryptococcosis.
Restrepo BI; Ahrens J; Graybill JR
Antimicrob Agents Chemother; 1989 Aug; 33(8):1242-6. PubMed ID: 2552903
[TBL] [Abstract][Full Text] [Related]
23. Dynamic interaction between fluconazole and amphotericin B against Cryptococcus gattii.
Santos JR; Gouveia LF; Taylor EL; Resende-Stoianoff MA; Pianetti GA; César IC; Santos DA
Antimicrob Agents Chemother; 2012 May; 56(5):2553-8. PubMed ID: 22290956
[TBL] [Abstract][Full Text] [Related]
24. Response to therapy in patients with cryptococcosis and AIDS: Association with in vitro susceptibility to fluconazole.
Agudelo CA; Muñoz C; Ramírez A; Tobón AM; de Bedout Bact C; Cano LE; Restrepo A
Rev Iberoam Micol; 2015; 32(4):214-20. PubMed ID: 25637338
[TBL] [Abstract][Full Text] [Related]
25. Central nervous system infection due to Cryptococcus gattii sensu lato in India: Analysis of clinical features, molecular profile and antifungal susceptibility.
Lahiri Mukhopadhyay S; Bahubali VH; Manjunath N; Swaminathan A; Maji S; Palaniappan M; Parthasarathy S; Chandrashekar N
Mycoses; 2017 Nov; 60(11):749-757. PubMed ID: 28736880
[TBL] [Abstract][Full Text] [Related]
26. [Clinical problems in medical mycology: problem number 43].
Negroni R; Lloveras S; Arechavala A; Maiolo E; Bianchi M; Santiso G; Messina F; Lehmann E; Walker L
Rev Iberoam Micol; 2012; 29(3):178-80. PubMed ID: 21872675
[No Abstract] [Full Text] [Related]
27. Fluconazole, with or without dexamethasone for experimental cryptococcosis: impact of treatment timing.
Lortholary O; Nicolas M; Soreda S; Improvisi L; Ronin O; Petitjean O; Dupont B; Tod M; Dromer F
J Antimicrob Chemother; 1999 Jun; 43(6):817-24. PubMed ID: 10404321
[TBL] [Abstract][Full Text] [Related]
28. Antimalarials and amphotericin B interact synergistically and are new options to treat cryptococcosis.
Freitas GJC; Ribeiro NQ; Gouveia-Eufrasio L; Emidio ECP; Guimarães GM; César IC; Paixão TA; Oliveira JBS; Caza M; Kronstad JW; Santos DA
Int J Antimicrob Agents; 2023 Jul; 62(1):106807. PubMed ID: 37030471
[TBL] [Abstract][Full Text] [Related]
29. Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil.
Herkert PF; Hagen F; de Oliveira Salvador GL; Gomes RR; Ferreira MS; Vicente VA; Muro MD; Pinheiro RL; Meis JF; Queiroz-Telles F
Eur J Clin Microbiol Infect Dis; 2016 Nov; 35(11):1803-1810. PubMed ID: 27477855
[TBL] [Abstract][Full Text] [Related]
30. Susceptibility to antifungal agents and genotypes of Brazilian clinical and environmental Cryptococcus gattii strains.
Silva DC; Martins MA; Szeszs MW; Bonfietti LX; Matos D; Melhem MS
Diagn Microbiol Infect Dis; 2012 Apr; 72(4):332-9. PubMed ID: 22341512
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection.
Lepak AJ; Zhao M; Berkow EL; Lockhart SR; Andes DR
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584152
[No Abstract] [Full Text] [Related]
32. Identification and properties of plasma membrane azole efflux pumps from the pathogenic fungi Cryptococcus gattii and Cryptococcus neoformans.
Basso LR; Gast CE; Bruzual I; Wong B
J Antimicrob Chemother; 2015 May; 70(5):1396-407. PubMed ID: 25630649
[TBL] [Abstract][Full Text] [Related]
33. Antifungal susceptibility of the clinical and environmental strains of Cryptococcus gattii sensu lato in Taiwan.
Lin KH; Lai YC; Lin YP; Ho MW; Chen YC; Chung WH
Mycoses; 2023 Jan; 66(1):13-24. PubMed ID: 35986599
[TBL] [Abstract][Full Text] [Related]
34. A murine model of Cryptococcus gattii meningoencephalitis.
Thompson GR; Wiederhold NP; Najvar LK; Bocanegra R; Kirkpatrick WR; Graybill JR; Patterson TF
J Antimicrob Chemother; 2012 Jun; 67(6):1432-8. PubMed ID: 22378683
[TBL] [Abstract][Full Text] [Related]
35. Cryptococcus gattii infection in solid organ transplant recipients: description of Oregon outbreak cases.
Forrest GN; Bhalla P; DeBess EE; Winthrop KL; Lockhart SR; Mohammadi J; Cieslak PR
Transpl Infect Dis; 2015 Jun; 17(3):467-76. PubMed ID: 25677448
[TBL] [Abstract][Full Text] [Related]
36. In-vitro and in-vivo activities of SCH56592 against Cryptococcus neoformans.
Hossain MA; Maesaki S; Mitsutake K; Kakeya H; Sasaki E; Tomono K; Tashiro T; Kohno S
J Antimicrob Chemother; 1999 Dec; 44(6):827-9. PubMed ID: 10590286
[TBL] [Abstract][Full Text] [Related]
37. Antifungal therapy in a murine model of disseminated infection by Cryptococcus gattii.
Calvo E; Pastor FJ; Rodríguez MM; Pujol I; Guarro J
Antimicrob Agents Chemother; 2010 Oct; 54(10):4074-7. PubMed ID: 20625150
[TBL] [Abstract][Full Text] [Related]
38. Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance.
Hope W; Stone NRH; Johnson A; McEntee L; Farrington N; Santoro-Castelazo A; Liu X; Lucaci A; Hughes M; Oliver JD; Giamberardino C; Mfinanga S; Harrison TS; Perfect JR; Bicanic T
mBio; 2019 Dec; 10(6):. PubMed ID: 31796539
[TBL] [Abstract][Full Text] [Related]
39. Hypervirulence and cross-resistance to a clinical antifungal are induced by an environmental fungicide in Cryptococcus gattii.
Carneiro HCS; Bastos RW; Ribeiro NQ; Gouveia-Eufrasio L; Costa MC; Magalhães TFF; Oliveira LVN; Paixão TA; Joffe LS; Rodrigues ML; Araújo GRS; Frases S; Ruiz JC; Marinho P; Abrahão JS; Resende-Stoianoff MA; Carter D; Santos DA
Sci Total Environ; 2020 Oct; 740():140135. PubMed ID: 32927573
[TBL] [Abstract][Full Text] [Related]
40. A new method for studying cryptococcosis in a murine model using 99mTc-Cryptococcus gattii.
Costa MC; Mata LM; Ribeiro NQ; Santos APN; Oliveira LVN; Vilela RVR; Cardoso VN; Fernandes SOA; Santos DA
Med Mycol; 2018 Jun; 56(4):479-484. PubMed ID: 28992125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
